Trial
NCT03575234
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Emory University
Collaborators
Bristol-Myers Squibb; Brooklyn ImmunoTherapeutics, LLC
Condition
Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
Intervention
Cyclophosphamide
Why stopped
funding and drug were withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-08-28